Vistagen Therapeutics, Inc. (NASDAQ:VTGN – Get Free Report) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 658,100 shares, a growth of 46.2% from the December 31st total of 450,000 shares. Currently, 2.6% of the shares of the stock are short sold. Based on an average daily volume of 276,000 shares, the days-to-cover ratio is currently 2.4 days.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the stock. R Squared Ltd acquired a new position in Vistagen Therapeutics during the 4th quarter worth approximately $25,000. Jane Street Group LLC bought a new position in shares of Vistagen Therapeutics during the third quarter valued at about $59,000. Virtu Financial LLC boosted its stake in shares of Vistagen Therapeutics by 30.5% in the 3rd quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock worth $61,000 after buying an additional 4,722 shares during the last quarter. HighTower Advisors LLC purchased a new stake in shares of Vistagen Therapeutics during the third quarter valued at approximately $64,000. Finally, Valence8 US LP bought a new position in Vistagen Therapeutics in the 3rd quarter valued at $103,000. Institutional investors and hedge funds own 78.39% of the company’s stock.
Vistagen Therapeutics Trading Up 2.8 %
VTGN stock opened at $2.94 on Friday. The company has a 50 day simple moving average of $2.77 and a 200 day simple moving average of $3.06. Vistagen Therapeutics has a 1 year low of $2.22 and a 1 year high of $5.74.
Vistagen Therapeutics Company Profile
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Recommended Stories
- Five stocks we like better than Vistagen Therapeutics
- How to Capture the Benefits of Dividend Increases
- Starbucks’ CEO-Led Turnaround Gains Traction: New Highs Likely
- Where to Find Earnings Call Transcripts
- 3 Chemical Stocks Defying Tariff Worries With Growth Potential
- Using the MarketBeat Dividend Tax Calculator
- How Growth Investors Find High-Growth Stocks and Maximize Returns
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.